Therapeutic implications of hypertension-induced glomerular injury: Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model

https://doi.org/10.1016/0002-9343(85)90078-6Get rights and content

Abstract

Systemic hypertension does not always reflect concomitant glomerular hypertension. At similar levels of systemic hypertension, glomerular injury occurs only in kidneys that lack protective preglomerular vasoconstriction, which results in glomerular hypertension. indeed, glomerular hypertension and glomerular injury do not develop in rats with spontaneous hypertension that have effective preglomerular vasoconstriction. In the experiments reported herein, the normal adaptive response (afferent arteriolar dilation) to a reduction of one and five-sixths of the renal mass in rats with spontaneous hypertension was examined to ascertain whether that response would expose the remaining nehprons to the injurious effects of high perfusion pressure. In addition, the efficacies of two different antihypertensive regimens were compared. Rats with spontaneous hypertension received either no therapy, or a combination of hydralazine, reserpine, and hydrochlorothiazide, or the angiotensin converting enzyme inhibitor enalapril. Three weeks after ablation of one and five-sixths of the renal mass, blood pressure, glomerular filtration rate, urinary protein excretion, and histologic injury scores for mesangial expansion and glomerulosclerosis were determined. Untreated rats with hypertension had severe glomerulosclerosis and mesangial expansion. Both antihypertensive regimens normalized systemic blood pressure and reduced glomerulosclerosis. However, enalapril was more effective than the combination of hydralazine, reserpine, and hydrochlorothiazide in reducing the exaggerated glomerular filtration rate (0.52 ± 0.40 versus 0.82 ± 0.10 ml perminute; p <0.05), the injury score for mesangial expansion (79 versus 103; p <0.05), and the degree of proteinuria (32 ± 4 versus 42 ± 3 mg per 24 hours; p <0.05). Persistence of hyperfiltration accompanied by increased mesangial expansion, may lead to progression of glomerular damage despite “adequate” control of systemic hypertension, as observed in rats treated with a combination of hydralazine, reserpine, and hydrochlorothiazide.

References (15)

  • L Raij et al.

    The glomerular mesangium: its function and relationship to angiotensin II

    Am J Med

    (1985)
  • F Delgreco et al.

    Hypertension of chronic renal failure: role of sodium and the renal pressor system

    Kidney Int

    (1975)
  • J Van Der Peet et al.

    The clinical course of IgA nephropathy in adults

    Clin Nephrol

    (1977)
  • PL Berry et al.

    Multicenter, collaborative clinicopathologic study of focal segmental glomerulosclerosis in children with nephrotic syndrome (abstr)

    Kidney Int

    (1984)
  • HA Austin et al.

    Prognostic factors in lupus nephritis: contribution of renal histologic data

    Am J Med

    (1983)
  • JS Cameron et al.

    Idiopathic mesangiocapillary glomerulonephritis: comparison of types I and II in children and adults and long-term prognosis

    Am J Med

    (1983)
  • L Raij et al.

    Mesangial immune injury, hypertension and progressive glomerular damage in Dahl rats

    Kidney Int

    (1984)
There are more references available in the full text version of this article.

Cited by (117)

  • Hypertensive nephrosclerosis

    2005, EMC - Nephrologie
  • Aldosterone in the development and progression of renal injury

    2004, Kidney International
    Citation Excerpt :

    The role of the RAAS in the development of renal injury has been demonstrated repeatedly in preclinical studies22-25. In stroke-prone spontaneously hypertensive rats and other experimental models, ACE inhibitors have been shown to block Ang II formation in the renal vasculature, reduce arterial vasoconstriction, and decrease glomerular capillary pressure22-25. The effect is at least partially independent of the blood-pressure lowering effects of these drugs.

View all citing articles on Scopus

This work was supported by a grant from the National Institutes of Health (HL-29720) and by funds from the Veterans Administration.

View full text